adequate evaluation of the efficacy of a given treatment regimen, which in turn can invalidate the results of a clinical trial. Risk factors for nonadherence among AYA patients include patients' emotional functioning (depression and poor/low self
Search Results
Peter F. Coccia, Alberto S. Pappo, Lynda Beaupin, Virginia F. Borges, Scott C. Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A. Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S. Huang, Michael P. Link, John A. Livingston, Yousif Matloub, Frederick Millard, Kevin C. Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R. Rosenberg, Tara Sanft, Holly L. Spraker-Perlman, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Nicholas Yeager, Lisa A. Gurski, and Dorothy A. Shead
Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, and Maoko Naganuma
damage, and stasis from direct vascular compression. 6 - 8 The incidence of cancer-associated VTE is further increased by the presence of additional risk factors, such as acquired or congenital thrombophilia (eg, antiphospholipid syndrome, factor V
Linda S. Overholser and Carlin Callaway
cause of death for adults in the US general population, is now known to be a leading cause of death in individuals treated for cancer. 7 – 12 As with cancer, CVD in survivors could be due to common behavioral risk factors, a family history, a late
Andrew T. Kuykendall and Rami Komrokji
corresponding risk category being assigned. 2 – 4 Additional risk factors have been proposed but not universally incorporated into risk-stratification models, including cardiovascular risk factors, leukocytosis, and, perhaps most controversially, platelet count
Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead
risk factor for the development of infections in patients undergoing chemotherapy. Effective strategies to anticipate, prevent, and manage infectious complications in neutropenic patients with cancer have led to improved outcomes. 1 – 12 Because of
Noopur S. Raje, Andrew J. Yee, and G. David Roodman
3.7 years. 35 Dental extractions are a major risk factor for the development of ONJ. 34 , 36 Attention to dental hygiene and minimizing invasive procedures (eg, tooth extractions, dental implants) may reduce the risk of ONJ. 37 IMWG guidelines
Judith A. Paice
. “For goal-setting surrounding pain, the focus has shifted from looking for zero on a pain scale to improving patients’ function. For a thorough assessment, we need to ask patients about risk factors for misuse. Family history is a crude proxy for risk
Renee W. Pinsky and Mark A. Helvie
area of tissue is known as percent mammographic density ( PMD ). Breast Density Measurement Recognition of breast density as a breast cancer risk factor and measurement of density have been evolving for more than 30 years. This affects a large number
Anne K. Hubben, Nathan Pennell, Marc Shapiro, Craig Savage, and James P. Stevenson
chemotherapy initiated between January 2016 and August 2018. PP pGCSF use was appropriate if prescribed with chemotherapy regimens with a high risk (>20%) for FN, or intermediate risk (10%–20%) if other accepted FN risk factors were present. PP use with FN low
Doralina L. Anghelescu, Jennifer Harman Ehrentraut, and Lane G. Faughnan
Treatment of chronic pain with opioids is associated with the risk of abuse, misuse, diversion, and addiction. 1 Patients receiving chronic opioid therapy (COT) for malignant or nonmalignant pain should be assessed for risk factors of abuse and
